Flag of the European Union EU Clinical Trials Register Help

Clinical trials for DIC

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    25 result(s) found for: DIC. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2010-024263-40 Sponsor Protocol Number: PEx in DIC Version 1 Start Date*: 2011-09-08
    Sponsor Name:Medizinische Universität Wien, Univ. Klinik f. Klinische Pharmakologie
    Full Title: Plasma exchange as therapy for disseminated intrevascular coagulation (DIC)- a randomized-controlled trial
    Medical condition: Disseminated intravascular coagulation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-002873-35 Sponsor Protocol Number: LEO 90010-I21 Start Date*: 2007-04-24
    Sponsor Name:LEO Pharmaceutical Products Ltd A/S (LEO Pharma A/S)
    Full Title: Exploratory efficacy and safety, pharmacokinetics and dose-finding study of ATryn® (antithrombin alfa) in patients with disseminated intravascular coagulation associated with severe sepsis
    Medical condition: Disseminated intravascular coagulation associated with severe sepsis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10013442 Disseminated intravascular coagulation LLT
    9.1 10040047 Sepsis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FR (Prematurely Ended) DE (Prematurely Ended) NL (Prematurely Ended) ES (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-002035-81 Sponsor Protocol Number: 2-001 Start Date*: 2007-10-22
    Sponsor Name:Artisan Pharma, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Safety and Efficacy Effects of ART-123 on Subjects with Sepsis and Disseminated Intravascular Coagulation
    Medical condition: Sepsis and disseminated intravascular coagulation.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10040047 Sepsis LLT
    9.1 10013442 Disseminated intravascular coagulation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) CZ (Completed) BE (Completed) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001599-13 Sponsor Protocol Number: TNKCAT Start Date*: 2021-08-13
    Sponsor Name:Hospital Vall Hebron
    Full Title: Tenecteplase Compared to Alteplase for Large Vesel Oclusion patients before Thrombectomy
    Medical condition: Acute Ischaemic Stroke
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-004726-42 Sponsor Protocol Number: 17/BW/MAT/PO14 Start Date*: 2017-02-15
    Sponsor Name:Birmingham Women's Hospital
    Full Title: Randomised controlled trial on the use of synthetic osmotic cervical dilator in induction of labour in comparison to dinoprostone vaginal insert
    Medical condition: Induction of Labour
    Disease: Version SOC Term Classification Code Term Level
    20.0 10036585 - Pregnancy, puerperium and perinatal conditions 10000154 Abnormal labour affecting foetus PT
    20.0 100000004849 10054386 Fetal heart rate disorder LLT
    20.0 10036585 - Pregnancy, puerperium and perinatal conditions 10046790 Uterine hypertonus PT
    20.0 10005329 - Blood and lymphatic system disorders 10013442 Disseminated intravascular coagulation PT
    20.0 10022117 - Injury, poisoning and procedural complications 10046820 Uterine rupture PT
    20.0 10021428 - Immune system disorders 10002198 Anaphylactic reaction PT
    20.0 100000004872 10018162 Genital oedema female LLT
    20.0 10036585 - Pregnancy, puerperium and perinatal conditions 10001971 Amniotic fluid embolism LLT
    20.0 10017947 - Gastrointestinal disorders 10028816 Nausea and vomiting LLT
    20.0 10017947 - Gastrointestinal disorders 10012735 Diarrhoea PT
    20.0 10036585 - Pregnancy, puerperium and perinatal conditions 10016492 Fetal distress syndrome LLT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2007-004884-24 Sponsor Protocol Number: X-03016-3271 Start Date*: 2008-08-04
    Sponsor Name:MEDA Pharma GmbH & Co. KG
    Full Title: Long-term effects of Aldara® 5% cream and Solaraze® 3% gel in the treatment of actinic keratoses on the face or scalp (LEIDA)
    Medical condition: This study will investigate the long term effects of Aldara® and Solaraze® on Actinic keratoses (AKs) on the face or scalp. AKs are defined as keratotic macules, papules or plaques with superficia...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000614 Actinic keratosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) AT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-002904-14 Sponsor Protocol Number: C14101 Start Date*: 2019-06-03
    Sponsor Name:Pharming Technologies B.V.
    Full Title: A Phase I/II, Open Label, Proof of Concept Study to investigate Tolerability and Safety of Treatment with Recombinant Human C1 Inhibitor in Patients with Preeclampsia.
    Medical condition: Preeclampsia
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-000769-13 Sponsor Protocol Number: AP SEP 02-02 Start Date*: 2006-06-13
    Sponsor Name:AM-Pharma
    Full Title: A double-blind, randomized, placebo-controlled study to investigate the clinical efficacy and safety of two doses of Alkaline Phosphatase administered for three days in patients with severe sepsi...
    Medical condition: Severe sepsis and septic shock
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-022054-16 Sponsor Protocol Number: X-03016-3284 Start Date*: 2011-09-05
    Sponsor Name:MEDA Pharma GmbH & Co. KG
    Full Title: Long-term effects of Aldara® 5% cream and Solaraze® 3% gel in the treatment of actinic keratoses on the face or scalp with respect to the risk of progression to in-situ and invasive squamous cel...
    Medical condition: This study will compare the long term effects of Aldara® and Solaraze® of the actinic keratoses on the face or scalp. Actinic keratoses (AKs) are defined as keratotic macules, papules or plaques w...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10000614 Actinic keratosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2005-000799-42 Sponsor Protocol Number: DIC 100-2004 Start Date*: 2005-07-13
    Sponsor Name:Mepha Ltd.
    Full Title: Randomised, double-blind, active-controlled, parallel-group, multicentre study comparing two slow release formulations of 100 mg diclofenac in patients with primary symptomatic osteoarthritis of th...
    Medical condition: Primary symptomatic osteoarthritis of the hip and/or knee
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-000888-26 Sponsor Protocol Number: DEV 1477-2 DIC 05 Start Date*: 2005-11-07
    Sponsor Name:ratiopharm GmbH
    Full Title: Randomised, double-blind, multi-centre, placebo-controlled clinical dose finding study in four parallel groups comparing Diclofenac Gel 1 %, Diclofenac Gel 3 %, Diclofenac Gel 5 % and placebo Gel i...
    Medical condition: Male or female ambulant patients (age range 18-60 years) suffering from fresh impact injuries (traumatic blunt soft tissue injury/contusion). Time elapse between traumatic event and inclusion must ...
    Disease: Version SOC Term Classification Code Term Level
    10022117 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-006349-23 Sponsor Protocol Number: HM08/8540 Start Date*: 2009-04-28
    Sponsor Name:The Leeds Teaching Hospitals NHS Trust
    Full Title: CMML201: A phase 2 study of azacitidine in chronic myelomonocytic leukaemia (CMML)
    Medical condition: Chronic Myelomonocytic Leukaemia (CMML): Patients with newly diagnosed or previously treated CMML-1 or CMML-2.
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009018 Chronic myelomonocytic leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-000707-81 Sponsor Protocol Number: VIPER-SEPSIS Start Date*: 2016-04-26
    Sponsor Name:Section for Transfusion Medicine, Capitol Region Blood Bank
    Full Title: Vasculopathic Injury and Plasma as Endothelial Rescue in septic shock (SEPSIS) trial
    Medical condition: Patients with septic shock admitted to the intensive care unit
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10040070 Septic shock PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-002281-23 Sponsor Protocol Number: Spon1345-14 Start Date*: 2016-06-13
    Sponsor Name:Cardiff University
    Full Title: A phase 2 study of the monocyte-targeted histone deacetylase inhibitor tefinostat (CHR-2845) in chronic myelomonocytic leukaemia (CMML)
    Medical condition: Chronic myelomonocytic leukaemia (CMML)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009018 Chronic myelomonocytic leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-000427-27 Sponsor Protocol Number: VIPER-SHOCK Start Date*: 2017-03-30
    Sponsor Name:Section for Transfusion Medicine, Capitol Region Blood Bank
    Full Title: Vasculopathic Injury and Plasma as Endothelial Rescue in septic shock (SHOCK) trial
    Medical condition: Patients with septic shock admitted to the intensive care unit.
    Disease: Version SOC Term Classification Code Term Level
    19.1 10021881 - Infections and infestations 10040070 Septic shock PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2020-001255-40 Sponsor Protocol Number: STRIKE-SARS-CoV2 Start Date*: 2020-04-16
    Sponsor Name:Clínica Universidad de Navarra/Universidad de Navarra
    Full Title: Sarilumab Treatment In cytoKinE storm caused by infection with COVID-19.
    Medical condition: Severe pneumonia caused by infection with SARS CoV 2.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10051905 Coronavirus infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-004834-32 Sponsor Protocol Number: PROTEINA-C Start Date*: 2012-06-08
    Sponsor Name:FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR
    Full Title: Administration of concentrated Protein C in patients with severe sepsis and contraindications to activated protein C. A monocentric, randomised placebo-controlled study.
    Medical condition: patients affected by severe sepsis admitted to intensive care
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10040047 Sepsis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-002254-31 Sponsor Protocol Number: THR-PS-03 Start Date*: 2011-11-29
    Sponsor Name:Rigshospitalet, ITA 4131, Department of Intensive care
    Full Title: Double-blinded, randomized trial in severe pneumonia patients with severe sepsis investigating the safety and efficacy of co-administration of iloprost and ascending doses of eptifibatide compared...
    Medical condition: Severe pneumonia with Sepsis and Septic Shock
    Disease: Version SOC Term Classification Code Term Level
    16.0 10021881 - Infections and infestations 10040070 Septic shock PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) FI (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-001872-54 Sponsor Protocol Number: ARC1779−006 Start Date*: 2009-01-24
    Sponsor Name:Archemix Corp
    Full Title: A Randomized, Double−blind, Placebo−controlled, Clinical Outcome Study of ARC1779 Injection in Patients with Thrombotic Microangiopathy.
    Medical condition: Thrombotic microangiopathy (TMA) disorders
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009731 Coagulation disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) AT (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-004972-49 Sponsor Protocol Number: CLFG316X2202 Start Date*: 2016-03-07
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, open label, controlled, multiple dose study to evaluate the clinical efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of LFG316 in patients with transplant ass...
    Medical condition: Transplant associated microangiopathy (TAM)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004866 10050444 Microangiopathy NOS LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) FR (Prematurely Ended) GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 03:46:16 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA